NDAINTRAVENOUSPOWDER
Approved
Jul 2021
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
MICAFUNGIN (micafungin sodium) by Teva is [see microbiology (12. Approved for fungal infection. First approved in 2021.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Micafungin sodium is an echinocandin antifungal agent administered intravenously as a powder for reconstitution. It treats invasive candidiasis, candidemia, esophageal candidiasis, and Candida meningoencephalitis, with linear dose-proportional pharmacokinetics across adult and pediatric populations (4 months+). The drug inhibits fungal cell wall synthesis through mechanisms targeting hematogenous Candida infections in immunocompromised patients including HIV+ and hematopoietic stem cell transplant recipients.
$0.006BPart D
PeakTeva's Micafungin is at peak lifecycle stage with modest Part D spending ($6K in 2023, 24 claims) but operates in a competitive therapeutic class; growth opportunities depend on branded vs. generic market dynamics.
Mechanism of Action
[see Microbiology (12.4)] . 12.2 Pharmacodynamics The pharmacodynamics of micafungin related to hematogenous Candida meningoencephalitis are described in other sections of the prescribing information [see Use in Specific Populations (8.4) and Microbiology (12.4)] . 12.3 Pharmacokinetics Adults The…
Worked on MICAFUNGIN at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.